Companies

Taysha Gene Therapies, Inc. (TSHA) SEC filings

CIK 0001806310 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in DE · fiscal year ends 12/31

Annual financials (from the company's own XBRL in its 10-K filings)

FY2025FY2024FY2023FY2022
Revenue (USD)9.8 M15.5 M2.5 M
Net income (USD)-111.6 M-166.0 M-174.5 M
Diluted EPS (USD/shares)-0.34-0.96-3.78

Latest filings

FiledFormDescriptionPeriod
2026-08-14SCHEDULE 13G/ASCHEDULE 13G/A
2026-08-13SCHEDULE 13G/ASCHEDULE 13G/A
2026-08-1110-Q10-Q2026-06-30
2026-08-118-K8-K items 2.02,9.012026-08-11
2026-07-10442026-07-10
2026-07-10144144
2026-06-258-K8-K items 1.01,8.01,9.012026-06-24
2026-06-25424B5424B5
2026-06-24424B5424B5
2026-06-228-K8-K items 7.01,8.01,9.012026-06-22
2026-06-02442026-06-01
2026-06-02442026-06-01
2026-06-02442026-06-01
2026-06-02442026-06-01
2026-06-028-K8-K items 5.072026-06-01
2026-05-15SCHEDULE 13G/ASCHEDULE 13G/A
2026-05-15SCHEDULE 13G/ASCHEDULE 13G/A
2026-05-0610-Q10-Q2026-03-31
2026-05-068-K8-K items 2.02,9.012026-05-06
2026-04-22ARSARS2025-12-31
2026-04-22DEFA14ADEFA14A
2026-04-22DEF 14ADEF 14A2026-06-01
2026-04-13442026-04-10
2026-04-10144144
2026-03-1910-K10-K2025-12-31

Forms on file (last 1,000): 4 106, 8-K 85, 144 32, 10-Q 18, SCHEDULE 13G/A 17, SC 13G/A 13, 3 12, SC 13G 12. Source: SEC EDGAR, as filed; this page is public data and not investment advice.

For software and AI agents: the same data as JSON, per call, no account: GET https://store.agentexchange.work/gw/filings/company?ticker=TSHA (0.002 USD), /gw/filings/filings?ticker=TSHA&form=8-K, /gw/filings/facts?ticker=TSHA&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txt

Updated from EDGAR within 30 minutes of a filing. Agent Exchange